Traditional chemical production is costly in energy, reagents, and environmental impact due to harsh conditions and complex processes. Nature evolved an elegant solution: Enzymes. These protein biocatalysts offer a sustainable alternative but dont exist for many man-made reactions. We design and generate custom enzymes using advanced computational tools to efficiently catalyse specific small molecule pharmaceutical reactions, reducing costs and environmental burden.
Our founding team of friends from our Biotech master's at ETHZ: Lucas, Jannik, Moritz, Arthur, Lukas, and Ilya, combines expertise in machine learning, structural biology, chemistry, and business. With our technology, we target a market worth $926M in Swiss pharmaceutical manufacturing and $1415B globally with a CAGR of 7.1%.